This article analyzes the singularity of historical, scientific, and political processes from the discovery of the disease caused by the myxoma virus (MYXV) that came to be known as infectious myxomatosis to the application of this virus against a plague of rabbits in Australia. This narrative focuses on research by Henrique de Beaurepaire Aragão, a researcher at the Oswaldo Cruz Institute, and later efforts by the scientist Jean Macnamara to promote studies and implement MYXV in Australia. The scientists' research notes were consulted, along with official documents recording the experiments and periodicals. In this process, the historical development of virology and biological controls as a field of study was also considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/S0104-59702021000500005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modified Vaccinia Virus Ankara Selectively Targets Human Cancer Cells With Low Expression of the Zinc-Finger Antiviral Protein.
J Med Virol
January 2025
National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Oncolytic viruses are emerging as promising cancer therapeutic agents, with several poxviruses, including vaccinia virus (VACV) and myxoma virus, showing significant potential in preclinical and clinical trials. Modified vaccinia virus Ankara (MVA), a laboratory-derived VACV strain approved by the FDA for mpox and smallpox vaccination, has been shown to be incapable of replicating in human cells unless zinc finger antiviral protein (ZAP) is repressed. Notably, ZAP deficiency is prevalent in various cancer types.
View Article and Find Full Text PDFTesting Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy.
Methods Mol Biol
December 2024
Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs.
View Article and Find Full Text PDFEvaluation of dried blood spots for serological surveys of myxoma and rabbit hemorrhagic disease viruses in their wild reservoir.
Prev Vet Med
January 2025
CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, InBIO Laboratório Associado, Universidade do Porto, Campus de Vairão, Vairão 4485-661, Portugal; BIOPOLIS Program in Genomics, Biodiversity and Land Planning, CIBIO, Campus de Vairão, Vairão 4485-661, Portugal; Estação Biológica de Mértola (EBM), CIBIO, Praça Luís de Camões, Mértola 7750-329, Portugal. Electronic address:
Article Synopsis
- Myxoma (MYXV) and rabbit hemorrhagic disease (RHDV) viruses are significant threats to European rabbits, which are now considered 'Endangered' in their native habitat.
- The study focused on evaluating the effectiveness of dried blood spots (DBS) for serological surveys of these viruses in European rabbits by comparing DBS to traditional serum samples.
- Results showed a high level of agreement between the two methods, with DBS demonstrating strong diagnostic sensitivity and perfect specificity for both MYXV and RHDV, confirming its viability for monitoring these diseases in the wild rabbit population.
Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma.
Int J Mol Sci
October 2024
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeże AK 15, 44-102 Gliwice, Poland.
Treatment of glioblastoma is ineffective. Myx-M011L-KO/EGFP, a myxoma virus actively inducing apoptosis in BTICs linked to recurrence, offers innovative treatment. We loaded this construct into adipose-derived stem cells (ADSCs) to mitigate antiviral host responses and enable systemic delivery.
View Article and Find Full Text PDFIL-12-mediated toxicity from localized oncolytic virotherapy can be reduced using systemic TNF blockade.
Mol Ther Oncol
September 2024
Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Cytokine therapy represents an attractive option to improve the outcomes of cancer patients. However, the systemic delivery of these agents often leads to severe immune-related toxicities, which can prevent their efficient clinical use. One approach to address this issue is the use of recombinant oncolytic viruses to deliver various cytokines directly to the tumor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!